Scopulariopsis brevicaulis, a fungal pathogen resistant to broad-spectrum antifungal agents
- PMID: 12821493
- PMCID: PMC161832
- DOI: 10.1128/AAC.47.7.2339-2341.2003
Scopulariopsis brevicaulis, a fungal pathogen resistant to broad-spectrum antifungal agents
Abstract
The antifungal susceptibility results for 32 clinical isolates of Scopulariopsis brevicaulis are presented. Flucytosine and itraconazole were inactive in vitro, and MICs of amphotericin B, voriconazole, and terbinafine for all isolates were high, with geometric means of 13, 25.8, and 14.4 microg/ml, respectively.
References
-
- Aberkane, A., M. Cuenca-Estrella, A. Gomez-Lopez, E. Petrikkou, E. Mellado, A. Monzon, and J. L. Rodriguez-Tudela. 2002. Comparative evaluation of two different methods of inoculum preparation for antifungal susceptibility testing of filamentous fungi. J. Antimicrob. Chemother. 50:719-722. - PubMed
-
- Bruynzeel, I., and T. M. Starink. 1998. Granulomatous skin infection caused by Scopulariopsis brevicaulis. J. Am. Acad. Dermatol. 39:365-367. - PubMed
-
- Denning, D. W., S. A. Radford, K. L. Oakley, L. Hall, E. M. Johnson, and D. W. Warnock. 1997. Correlation between in-vitro susceptibility testing to itraconazole and in-vivo outcome of Aspergillus fumigatus infection. J. Antimicrob. Chemother. 40:401-414. - PubMed
-
- Dhar, J., and P. B. Carey. 1993. Scopulariopsis brevicaulis skin lesions in an AIDS patient. AIDS 7:1283-1284. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources